Navigation Links
Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011

ANAHEIM, Calif., Oct. 11, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release third quarter 2011 financial results on Tuesday, October 25, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and slide presentation via webcast on Tuesday, October 25, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the third quarter, as well as current corporate developments.  

Conference call details:Date:Tuesday, October 25, 2Time:4:30 p.m. ETDial-in (U.S.):877-941-1465Dial-in (International):480-629-9643Web cast:www.questcor.comTo access an audio replay of the call:

Replay (U.S.):800-406-7325Replay (International):303-590-303Replay Passcode:4480054About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
3. Questcor Provides Updated New Paid Prescription Trends
4. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
5. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
6. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
7. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
8. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
9. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
10. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
11. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... Officer Antonius Schuh, Ph.D., is scheduled to present a ... Jaffray Healthcare Conference. th Annual Piper ... in New York on Tuesday, ... will be available for one-on-one meetings during the conference. ...
(Date:11/25/2015)... , November 25, 2015 ... self-monitoring blood glucose devices was valued at $11,171.1 million ... a CAGR of 5.7% during 2015 - 2022. The ... and increasing prevalence of diabetes. In addition, the increase ... is also contributing to the growth of the market. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
(Date:11/25/2015)... ... 2015 , ... Lakeview Health, a Jacksonville-based drug and alcohol ... and show through pictures what a positive difference it makes. The social media ... hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories can ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
Breaking Medicine News(10 mins):